Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986053 | 0.78 | MEN1 (0.46) | MEN1KMT2APOLBSMN1; SMN2CTSS | |
| Hydrochloric Acid SCHEMBL7046065 | 0.78 | ALDH1A1 (0.41) | MEN1KMT2APOLBCA12CA1 | |
| SCHEMBL1929388 | 0.75 | ROCK2 (0.47) | MEN1KMT2ASMN1; SMN2CTSSTACR1 | |
| SCHEMBL503402 | 0.75 | MEN1 (0.57) | MEN1KMT2APOLBSMN1; SMN2CTSS | |
| SCHEMBL14151548 | 0.75 | SMN1; SMN2 (0.46) | MEN1KMT2APOLBSMN1; SMN2CTSS | |
| SCHEMBL8880230 | 0.75 | ATM (0.46) | POLBCTSSSYKATM | |
| SCHEMBL4442846 | 0.75 | KMT2A (0.60) | MEN1KMT2APOLBSMN1; SMN2CTSS | |
| SCHEMBL11838904 | 0.74 | ALDH1A1 (0.40) | MEN1KMT2APOLBCA12CA1 | |
| SCHEMBL26791515 | 0.74 | SMN1; SMN2 (0.46) | MEN1KMT2APOLBSMN1; SMN2CTSS | |
| SCHEMBL6444094 | 0.74 | MEN1 (0.56) | MEN1KMT2APOLBSMN1; SMN2CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| EP-4359081-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | KRAS, NRAS, APC | MEN1 1128/4885KMT2A 3143/4885POLB 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.